Novavax | NVAX - Ebitda


Novavax reported $19.36M in EBITDA for its fiscal quarter ending in December of 2025.





Ebitda Change Date
Adma Biologics USD 55.44M 5.62M Jun/2026
Agenus USD -10.11M 19.02M Mar/2025
AstraZeneca USD 7.46B 2.3B Sep/2026
BioCryst Pharmaceuticals USD 51.7M 30.14M Sep/2025
Cassava Sciences USD -11.73M 33.44M Sep/2025
Geron USD -9.2M 13.03M Jun/2026
GlaxoSmithKline GBP 3.51B 734M Jun/2026
MannKind USD 2.47M 461K Jun/2026
Merck USD 1.42B 2.97B Jun/2026
Minerva Neurosciences USD -4.36M 1.71M Sep/2024
Moderna USD -687M 571M Jun/2026
Novartis USD 5.36B 45M Sep/2026
Novavax USD 19.36M 190.79M Dec/2025
Pfizer USD 6.36B 350M Sep/2026
Sanofi EUR 5.79B 2.1B Sep/2026
Sarepta Therapeutics USD -3.14M 33.31M Sep/2026
TG Therapeutics USD 26.9M 1.21M Jun/2026